Drugs / CNM-ZnAg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04610138 | Jun 2021 → May 2022 | COVID-19 | Clene Nanomedicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNM-ZnAg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04610138 ↗ |
| Route | Oral | “60 ml low-dose ZnAg (Zn 6 ug/ml and Ag 10 ug/ml; equivalent to 0.6 mg Ag, 0.36 mg Zn), po q12 hours” NCT04610138 ↗ |